Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Skin Neoplasms 1Prostatic Neoplasms 1Oligodendroglioma 1Melanoma 1Lymphoma, Follicular 1Lung Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

Rituximab 59Cyclophosphamide 29fludarabine phosphate 20Bortezomib 16Filgrastim 15Tacrolimus 12Mycophenolic Acid 12Methotrexate 12Radiotherapy 11Peripheral Blood Stem Cell Transplantation 11Cyclosporine 11Antilymphocyte Serum 11Whole-Body Irradiation 10fludarabine 8Etoposide 8venetoclax 7sargramostim 7idelalisib 7ibritumomab tiuxetan 7Melphalan 7Lenalidomide 7Cord Blood Stem Cell Transplantation 7Busulfan 7Bendamustine Hydrochloride 7Vincristine 6Prednisone 6Granulocyte Colony-Stimulating Factor 6obinutuzumab 5Gemcitabine 5umbralisib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Follicular × varlilumab × Clear all
NCT02924038 2024-06-14

A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)

University of California, San Francisco

Phase 1 Terminated
14 enrolled 10 charts
CNSLymphoid

Astrocytoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡